1
Open
[.]
2
Close
[.]
3
Allotment
—
4
Listing
[.]
Issue Size
[.] shares (agg. up to ₹3,000 Cr)
Listing Date
[.]
✦ AI Insight
Restated Financials (₹ Cr.)
| Period Ended | 31 Mar 2026 | 31 Mar 2025 | 31 Mar 2024 |
|---|---|---|---|
| Assets | 2,792.10 | 2,300.10 | 1,871.80 |
| Total Income | 1,911.80 | 1,369.00 | 1,098.20 |
| Profit After Tax | 436.70 | 249.60 | 156.10 |
| EBITDA | 663.30 | 452.10 | 297.60 |
| NET Worth | 1,953.60 | 1,512.80 | 1,258.40 |
| Reserves and Surplus | 1,915.20 | 1,495.20 | 1,243.40 |
| Total Borrowing | 221.70 | 230.50 | 228.10 |
| Amount in ₹ Crore |
Peer Comparison
| Company | Issue Type | Issue Size | Issue Price | PE Ratio | Listing Day Close | Listing Gain/Loss % | LTP |
|---|---|---|---|---|---|---|---|
| Hexagon Nutrition Ltd. | Mainboard | ₹138.87 Cr | ₹45 | 22.69 | ₹53.19 | +18.20% | ₹66.41 |
| Sai Parenteral's Ltd. | Mainboard | ₹408.79 Cr | ₹392 | 72.19 | ₹405.70 | +3.49% | ₹542.05 |
| Corona Remedies Ltd. | Mainboard | ₹655.37 Cr | ₹1062 | 43.47 | ₹1,438.40 | +35.44% | ₹2,119.40 |
| Rubicon Research Ltd. | Mainboard | ₹1,377.50 Cr | ₹485 | 55.75 | ₹628.20 | +29.53% | ₹1,804.10 |
| Amanta Healthcare Ltd. | Mainboard | ₹126.00 Cr | ₹126 | 34.59 | ₹141.75 | +12.50% | ₹172.29 |
| Anlon Healthcare Ltd. | Mainboard | ₹121.03 Cr | ₹91 | 17.67 | ₹91.73 | +0.80% | ₹14.63 |
| Bio Medica Laboratories Ltd. | SME | ₹52.43 Cr | ₹139 | 13.03 | ₹115.80 | -16.69% | ₹154.90 |
| Goldline Pharmaceutical Ltd. | SME | ₹11.61 Cr | ₹43 | 10.47 | ₹56.77 | +32.02% | ₹40.09 |
| Speciality Medicines Ltd. | SME | ₹29.14 Cr | ₹124 | 9.27 | ₹125.90 | +1.53% | ₹167.95 |
| Accretion Nutraveda Ltd. | SME | ₹24.77 Cr | ₹129 | 26.27 | ₹191.20 | +48.22% | ₹282.75 |
| KRM Ayurveda Ltd. | SME | ₹77.49 Cr | ₹135 | 17.32 | ₹180.70 | +33.85% | ₹281.70 |
| Curis Lifesciences Ltd. | SME | ₹27.52 Cr | ₹128 | 12.44 | ₹141.00 | +10.16% | ₹110.20 |
| Aptus Pharma Ltd. | SME | ₹13.02 Cr | ₹70 | 11.29 | ₹84.84 | +21.20% | ₹273.95 |
About Encube Ethicals IPO
Incorporated in September 1995, Encube Ethicals Limited is a global pharmaceutical formulations company specializing in topical and transdermal dosage forms, serving 50 countries, including regulated markets such as the United States, the UK, Europe, and India. The company operates through three integrated business verticals: Global Generics, Global CDMO (Contract Development and Manufacturing Organization), and India Branded Formulations, providing end-to-end capabilities across research & development, formulation development, manufacturing, regulatory compliance, and commercialization. It is one of the fastest-growing players in the US topical generics market and has a strong presence in regulated international markets. Encube operates large-scale regulatory-approved manufacturing facilities supported by advanced R&D infrastructure, a robust innovation pipeline, and long-standing relationships with leading global pharmaceutical companies. The company also markets branded topical products in India through an established distribution network. Encube focuses on innovation, quality, regulatory compliance, and customer-centric product development. As of March 31, 2026, the company had
Contact Details
Encube Ethicals Ltd. Address803, B WingHDIL Kaledonia, Sahar RoadAndheri EastMumbai, Maharashtra, 40006922 62288000compliance.cs@encubeethicals.comVisit Website